DOCSLIB.ORG

Fragances Extracts

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

PERSONAL CARE extracts petroleum jellies and paraffins active ingredients antioxidants hair conditioners oils amino acids colourants emollients preservatives fragances vitamins emulsifiers fatty alcohols sunscreens multifunctionals waxes pearl shine concentrates moisturisers opacifiers At Escuder, we are specialists in distributing raw materials aimed primarily at the cosmetics, pharmaceutical, veterinary, food and dietary industries. Since 1896, our aim has been to provide the highest quality in our services and products. Escuder is a dynamic company, with a highly specialised team and all the necessary resources to constantly update our processes and incorporate new tools which enable us to establish close connections with our customers and suppliers. Our extensive experience, sound industry knowledge, reliability and professionalism allow us to adapt to our customers’ needs, providing the highest levels of quality and safety in managing the products and services we offer. This is our catalogue of products aimed primarily at the cosmetics industry. Here you will find a wide range of materials which we hope will be of interest to you and meet your needs. Actives 4-7 Amino Acids 7 Antibacterials, Antifungals 8 Antioxidants 8 Emollients 8-9 Emulsifiers / Fatty Alcohols 10-11 Exfoliants 11 Extracts 12 Fragrances 12 Hair Conditioners 13 Humectants 14 Oils 14-15 Pearl Shine Concentrates / Opacifiers 15 Ph Regulators 15 Preservatives 16 Rheological Modifiers 17 Sequestrant Agents 17 Solubilizers 17 Sunscreen Filters 18 Surfactants 18-19 Sweeteners 19 Thickening Agents 20 Petroleum Jellies and Paraffins 20 Vitamins 21 Waxes 21 Other products 22 -3- A Actives Code Description Inci Activity 20123 18 B-GLYCYRRHETINIC ACID EP GLYCYRRHETINIC ACID ANTI-INFLAMMATORY / ANTIRRITANT / RELAXING 20436 ALLANTOIN EP ALLANTOIN HEALING, REGENERATING, DRY SKIN 20126 AZELAIC ACID AZELAIC ACID ANTI-ACNE 20914 BIO PROTEINOL PF PLACENTAL PROTEIN MOISTURIZING, HAIR CARE 20912 BIOSULPHUR FLUID SULFUR, PEG-30 CASTOR OIL REGULATOR OF SEBACEOUS SECRETION, ANTI DANDRUFF, ANTISEPTIC, ANTI-ACNE 20918 BIOSULPHUR POWDER SULFUR (80-85%), AGAR (5-10%), ACACIA REGULATOR OF SEBACEOUS SECRETION, SENEGAL GUM (5-10%) ANTI DANDRUFF, ANTISEPTIC, ANTI-ACNE 20994 CAFFEINE PURE EP CAFFEINE ANTI-CELLULITE, MOISTURIZING, PHLEBOTONIC 20446 CAMPHOR CRYSTAL CAMPHOR STIMULATING, COOLING EFFECT, BLOOD CIRCULATION IMPROVER 21146 CARNITINE BASE-L CARNITINE ANTI-CELLULITE, ANTI-STRETCH MARKS, REAFFIRMING 21147 CARNITINE DL HYDROCHLORIDE CARNITINE HCL ANTI-CELLULITE, ANTI-STRETCH MARKS, REAFFIRMING 21161 CEGABA 100% POWDER CARBOXYETHYL AMINOBUTYRIC ACID STIMULATING HAIR GROWTH 29642 DERMAWHITE NF LS 9410 MANNITOL (AND) SODIUM GLUCONATE (AND) WHITENING CITRIC ACID (AND) SODIUM CITRATE (AND) WALTHERIA INDICA EXTRACT (AND) DEXTRIN (AND) FERULIC ACID 29651 DERMOSACCHARIDES GY AQUA (AND) GLYCERIN (AND) GLYCOGEN STIMULATING HAIR GROWTH, ANTI-HAIR LOSS 21505 DIHYDROXYACETONE DIHYDROXYACETONE SELF-TANNING -4- A Actives Code Description Inci Activity 20378 ELASTIN AQUA(>50%), HYDROLYZED ELASTIN (1%-5%), IMPROVE RESISTANCE AND ELASTICITY PHENOXYETHANOL (0.1%-1%), SORBIC ACID (0.1-1%) 60140 EUCALYPTOL EUCALYPTOL ANTISEPTIC, HEALING, ANTI- INFLAMMATORY, DECONGESTANT, SOOTHING 20248 HYALURONIC ACID SODIUM SALT AQUA ( >95%), SODIUM HYALURONATE (0,5- MOISTURIZING, ANTI-FREE RADICALS, PRO 2%), PHENOXYETHANOL (0,9%) AGE, REAFFIRMING 22399 HYDAGEN CAT TRIETHYL CITRATE DEODORANT 20660 ICHTHAMMOL EP ICHTHAMMOL ANTISEPTIC, ANTIBACTERIAL 22418 IODOTRAT TEA HYDROIODIDE ANTI-CELLULITE 20153 KOJIC ACID KOJIC ACID WHITENING 29644 LACTOLAN LS 5879 HYDROLIZED MILK PROTEIN HAIR CARE, CONDITIONER, UV PROTECTOR, ANTI-CURLING, MOISTURIZING 24486 LIPACIDE C8G CAPRYLOYL GLYCINE ANTI DANDRUFF, DERMO PROTECTION, SENSITIVE SKIN 29638 MELHYDRAN LS 4420 MEL EXTRACT MOISTURIZING, DERMO PROTECTION 22705 MENTHOL CRYSTAL 42/44 MENTHOL COOLING EFFECT 60190 MENTHOL PELLETS MENTHOL COOLING EFFECT 22792 METHYL NICOTINATE METHYL NICOTINATE VASODILATOR, RUBEFACIENT, THERMOGENIC 27538 METHYL SALICYLATE METHYL SALICYLATE ANTI-INFLAMMATORY, ANALGESIC, RUBEFACIENT, THERMOGENIC -5- A Actives Code Description Inci Activity 21144 METHYLSULFONYLMETHANE DIMETHYL SULFONE ANTI-INFLAMMATORY, REGENERATING, DRY SKIN 29699 MYOXINOL LS 9736 HYDROLYZED HIBISCUS ESCULENTUS EXTRACT PRO AGE (AND) DEXTRIN 23442 ORGANIC SILICON METHYLSILANOL MANNURONATE REAFFIRMING, CONFORTING, ANTI- WRINKLES, MOISTURIZING 29629 PILINHIB VEG LS 9109 PROPYLENE GLYCOL (AND) HYDROLYZED SOY HAIR GROWTH INHIBITOR PROTEIN (AND) HYPERICUM PERFORATUM EXTRACT (AND) HAMAMELIS VIRGINIANA EXTRACT (AND) ARNICA MONTANA EXTRACT (AND) UREA (AND) SALIX ALBA BARK EXTRACT (AND) MENTHOL (AND) SALICYLIC ACID 23098 PIROCTONE OLAMINE PIROCTONE OLAMINE ANTI-DANDRUFF 20313 SALICYLIC ACID EP SALICYLIC ACID ANTI-ACNE, REGENERATING, PEELING 20311 SALICYLIC ACID POWDER SALICYLIC ACID ANTI-ACNE, REGENERATING, PEELING 29663 SEBARYL FL LS 9088 AQUA (AND) NIACINAMIDE (AND) FAEX REGULATOR OF SEBACEOUS SECRETION EXTRACT (AND) AESCULUS HIPPOCASTANUM EXTRACT (AND) AMMONIUM GLYCYRRHIZATE (AND) PANTHENOL (AND) PROPYLENE GLYCOL (AND) ZINC GLUCONATE (AND) CAFFEINE (AND) BIOTIN 23932 SODIUM FLUORIDE EP/USP SODIUM FLUORIDE ANTI-CAVITIES 20773 SULFUR FLOWER WASHED EP SULFUR REGULATOR OF SEBACEOUS SECRETION, ANTI- DANDRUFF, ANTISEPTIC, ANTI- ACNE 24085 TIOXOLONE TIOXOLONE REGULATOR OF SEBACEOUS SECRETION, ANTI-ACNE -6- A Actives Code Description Inci Activity 29655 TRICHOGEN VEG LS 8960 AQUA (AND) PANAX GINSENG ROOT EXTRACT ANTI-HAIR LOSS ACTIVE AND (AND) ARGININE (AND) ACETYL TYROSINE CONDITIONER (AND) ARCTIUM MAJUS ROOT EXTRACT (AND) HYDROLYZED SOY PROTEIN (AND) POLYQUATERNIUM-11 (AND) DIMETHICONE COPOLYOL (AND) CALCIUM PANTOTHENATE (AND) ZINC GLUCONATE (AND) NIACINAMIDE (AND) ORNITHINE HCL (AND) CITRULLINE (AND) GLUCOSAMINE HCL (AND BIOTIN 24274 UREA Q.P. UREA MOISTURIZING, KERATOLYTIC, ESCCHAROTIC EFFECTS. 29648 VEGESERYL HGP LS 8572 GLYCINE SOJA PROTEIN PRO AGE, ANTI-RIDES, CONFORTING 29637 VITACELL LS 8430 FAEX EXTRACT REGENERATING, REVITALIZING 24504 ZINC OXIDE EP (LIGHT) ZINC OXIDE ANTI-IRRITANT, COOLING EFFECT 24509 ZINC PYRITHIONE ZINC PYRITHIONE ANTI-DANDRUFF 24511 ZINC PYRITHIONE 48% SOLUTION ZINC PYRITHIONE (48-50%), AQUA (44-46%), ANTI-DANDRUFF PROPYLENE GLYCOL (APROX. 2,8%), SODIUM POLYNAPHTHALE NESULFONATE (0,5%), XANTHAN GUM (APROX. 0,2%), SODIUM CHLORIDE (APROX. 0,2%), MAGNESIUM NITRATE, METHYLCHLOROISOTHIAZOLINONE, MAGNESIUM CHLORIDE, METHYLISOTHIAZOLINONE Amino Acids Code Description Inci 20433 ALANINE-L ALANINE 20734 ARGININE BASE EP ARGININE 20736 ARGININE CHLORIDE EP ARGININE HCL 22238 GLUTAMINE-L GLUTAMINE 22214 GLYCINE EP GLYCINE 22538 LYSINE-L MONOHYDROCHLORIDE LYSINE HCL 22796 METHIONINE-L METHIONINE 22119 PHENYLALANINE-L PHENYLALANINE 23342 PROLINE-L PROLINE 23446 SERINE-L EP SERINE 23883 TAURINE TAURINE -7- A Antibacterials, Antifungals Code Description Inci 20558 ALUMINIUM CHLOROHYDRATE ALUMINIUM CHLOROHYDRATE 21253 ALUMINIUM CHLOROHYDROXIDE ALUMINIUM CHLOROHYDRATE (50-70%), ALLANTOIN (30-50%) ALLANTOINATE 20816 BENZALKONIUM CHLORIDE 80% BENZALKONIUM CHLORIDE (APROX. 80%), AQUA (12-16%), METHANOL (4-8%) 20179 BORIC ACID POWDER EP BORIC ACID 21206 CETRIMIDE EP MYRTRIMONIUM BROMIDE 21255 CLORHEXIDINE DIGLUCONATE 20% EP AQUA (75-85%),CLORHEXIDINE DIGLUCONATE (19-21%) 22399 HYDAGEN CAT TRIETHYL CITRATE 23742 SODIUM TIOSULPHATE CRYSTAL EP SODIUM TIOSULPHATE 24122 TRICLOSAN TRICLOSAN 20365 UNDECYLENIC ACID EP UNDECYLENIC ACID 24500 ZINC GLUCONATE EP ZINC GLUCONATE Antioxidants Code Description Inci 20902 B.H.A./ BUTYL HYDROXY ANISOLE E320 BHA 20907 B.H.T./ BUTYL HYDROXY TOLUENE E321 BHT 23586 SODIUM CITRATE EP E331 SODIUM CITRATE 20242 THIOCTIC ACID (ALPHA LIPOIC) THIOCTIC ACID E Emollients Code Description Inci 25010 ABIL CUTANEOUS STEAROXY DIMETHICONE 25006 ABIL GRAS PEG/PPG-14/4 DIMETHICONE (aprox. 95%), PROPYLENE GLYCOL (aprox. 5%), PENTAERYTHRITYL TETRA-DI-T-BUTYL HYDROXYHYDROCINNAMATE (0,03%) TRIISOPROPANOLAMINE (0,02%) 25011 ABIL WE 09 POLYGLYCERYL-4-ISOSTEARATE, CETYL PEG/PPG-10/1 DIMETHICONE, HEXYL LAURATE 20491 ACETYLATED LANOLIN ALCOHOL ACETYLATED LANOLIN ALCOHOL (AND), CETYL ACETATE (AND) OLEYL ACETATE 21097 CAPRYLIC CAPRIC TRIGLYCERIDES EP CAPRYLIC CAPRIC TRIGLYCERIDE 25063 CETIOL 868 ETHYLHEXYL STEARATE -8- E Emollients Code Description Inci 21199 CETIOL B DIBUTYL ADIPATE 21110 CETIOL C5 COCO-CAPRYLATE 21194 CETIOL CC DICAPRYLYL CARBONATE 21201 CETIOL HE PEG-7 GLYCERYL COCOATE 21204 CETIOL J 600 OLEYL ERUCATE 21202 CETIOL LC COCO-CAPRYLATE, CAPRATE 21209 CETIOL OE DICAPRYLYL ETHER 21210 CETIOL SB-45 (KARITE BUTTER) BUTYROSPERMUM PARKII BUTTER 40076 CETIOL SENSOFT PROPYLHEPTYL CAPRYLATE 21203 CETIOL SN CETEARYL ISONONANOATE 21117 CETIOL ULTIMATE UNDECANE (AND) TRIDECANE 21200 CETIOL V DECYL OLEATE 22670 COCOA BUTTER THEOBROMA CACAO SEED BUTTER 21424 CUTINA CP CETYL PALMITATE 25703 DERMALIP HE PEG-7 GLYCERYL COCOATE 21870 EUTANOL G OCTYLDODECANOL 22819 ISOPROPYL MYRISTATE EP ISOPROPYL MYRISTATE 22964 ISOPROPYL PALMITATE ISOPROPYL PALMITATE 22675 KARITE BUTTER G.H. BUTYROSPERMUM PARKII BUTTER 21237 KOLLICREAM OD OCTYLDODECANOL 40041 LAMESOFT PO 65 COCO-GLUCOSIDE, GLYCERYL OLEATE 22453 LANOLIN ANHIDRA EP LANOLIN 22460 LIQUID LANOLIN LANOLIN OIL 22849 MYRITOL 318 CAPRYLIC CAPRIC TRIGLYCERIDE 22850 MYRITOL 331 COCOGLYCERIDES 25711 NEOPAL WG/50 PEG-75 LANOLIN (40-60%), AQUA (40-60%) 22948 OCTYL PALMITATE ETHYLHEXYL PALMITATE 25727 ROFETAN DO DECYL OLEATE 20075 SILICONE OIL 100 cps. DIMETHICONE 20079 SILICONE OIL 350 cps. DIMETHICONE 22140 SQUALANE VEGETAL SQUALANE -9- E Emulsifiers
Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • Survey and Risk Assessment of Chemical Substances in Deodorants

    Survey and Risk Assessment of Chemical Substances in Deodorants

    Survey and risk assessment of chemical substances in deodorants Suresh C. Rastogi & Gitte Hellerup Jensen National Environmental Research Institute Jeanne Duus Johansen National Allergy Research Centre Survey of Chemical Substances in Consumer Products, No. 86 2007 The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA. Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA. The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark. Contents SAMMENFATNING 5 SUMMARY 7 1 INTRODUCTION 11 2 MARKET SURVEY AND PRODUCT SAMPLING 13 2.1 MARKET SURVEY 13 2.2 LEGISLATION 15 2.3 SAMPLING OF PRODUCTS AND CONTROL OF LABELLING 15 2.4 SELECTION OF PRODUCTS FOR ANALYSIS 18 3 ANALYSIS 19 3.1 MATERIALS 19 3.2 ANALYSIS 19 3.2.1 Sample preparation 19 3.2.2 Analysis of fragrance substances 19 3.2.3 Analysis of triclosan 20 4 RESULTS 21 5 RISK ASSESSMENT 27 5.1 DEODORANTS AND CONTACT ALLERGY 27 5.2 RISK ASSESSMENT – IN GENERAL 27 5.3 THE SELECTED FRAGRANCE SUBSTANCES 28 5.3.1 HYDOXYISOHEXYL 3-CYCLOHEXENE CARBOXALDEHYDE (HICC) 28 5.3.2 HYDROXYCITRONELLAL 32 5.3.3 ISOEUGENOL 33 5.3.4 CINNAMAL/CINNAMYL ALCOHOL 34 5.4 FARNESOL 35 5.5 COMMENTS CONCERNING OTHER FRAGRANCE SUBSTANCES 35 5.6 ALLERGEN LOAD OF FRAGRANCE SUBSTANCES 36 5.7 TRICLOSAN 36 6 DISCUSSION 38 7 REFERENCES 43 ANNEX 1 49 3 4 Sammenfatning Deodoranter anvendes dagligt af store dele af befolkningen og kan indeholde ingredienser, som visse duftstoffer og konserveringsmidler, der er hyppige år- sager til hudallergi.
  • Novel Derivatives of Bio-Affecting Phenolic Compounds and Pharmaceutical Composition Containing Them

    Novel Derivatives of Bio-Affecting Phenolic Compounds and Pharmaceutical Composition Containing Them

    Europaisches Patentamt European Patent Office © Publication number: 0046 270 A1 Office europeen des brevets ™ EUROPEAN PATENT APPLICATION @ Application number: 81106277.7 © Int. CI.3: C 07 C 103/78, C 07 C 93/26, C 07 C 69/24, C 07 C 1 53/07, @ Date of filing: 12.08.81 C07C 69/28 // C07C1 25/065 <§) Priority: 13.08.80 US 177825 © Applicant: INTERx RESEARCH CORPORATION, 2201 West 21 st Street, Lawrence Kansas 66044 (US) © I nventor : Bodor, Nicholas S., 31 5 Southwest 91 st Street, ® Dateofpublicationofapplication:24.02.82 S^^S^mHariMBM Bulletin m/b Terrace, Gainesville, Florida 32605 (US) Inventor: Pogany, Stefano A., 520 Louisiana Street, Lawrence Kansas 66044 (US) @ Designated Contracting States : AT BE CH DE FR GB IT ® Representative: Abitz, Walter, Dr.-lng. et al, Abitz, Mori, LI LU NL SE Gritschneder P.O. Box 86 01 09, D-8000 Munchen 86 (DE) Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them. Novel@ Novel transient prodrug forms of bio-affecting phe- amyl, CH2ONO2,CH2ON02, -CH2OCOR2 or any non-heterocyclic nolic compounds are selected from the group consisting of member of the group defined by R2Rz above; and n.isn is at least those having the structural formula (I): one and equals the total number of phenolic hydroxyl functions comprising the non-steroidal bioaffecting phenol o etherified via a R2COXCH(R3)0-moiety; those having the structural formula (II): R2-C-X-CH-0- (I) I O R, II R2-C-X-CH-0- -RM-i-O-C-R2 (II) wherein X is O, S or NR5 wherein R5 is hydrogen or lower alkyl;alky!;
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann Et Al

    US 2014O127257A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann et al. (43) Pub. Date: May 8, 2014 (54) DERMATOLOGICALLY EFFECTIVE YEAST Publication Classification EXTRACT (51) Int. Cl. (75) Inventors: Yvonne Schiemann, Essen (DE); Mike A61E36/064 (2006.01) Farwick, Essen (DE); Thomas Haas, CI2P I/02 (2006.01) Muenster (DE); Mirja Wessel, Bochum A61E36/06 (2006.01) (DE) (52) U.S. Cl. CPC ............... A61K 36/064 (2013.01); A61K 36/06 (73) Assignee: EVONIK DEGUSSA GMBH, Essen (2013.01); CI2P I/02 (2013.01) (DE) USPC ...................................... 424/195.16; 435/171 (21) Appl. No.: 14/128,244 (22) PCT Fled: Jun. 14, 2012 (57) ABSTRACT (86) PCT NO.: PCT/EP2012/061263 The invention relates to a method for producing a dermato S371 (c)(1), logically active yeast extract, comprising the following steps: (2), (4) Date: Dec. 20, 2013 providing a preculture of the yeast cells, culturing the cells for (30) Foreign Application Priority Data at least fifteen minutes at a pH of 1.8-4, harvesting the cells and lysing the cells, and a yeast extract produced thereby and Jun. 29, 2011 (EP) .................................. 11171953.0 products comprising said yeast extract. Patent Application Publication May 8, 2014 Sheet 1 of 3 US 2014/O127257 A1 -0-Yarrowia------------ lipolytica -- Pichia CBS 1991 - A - Saccharomyces Cerevisiae Fig. 1 US 2014/O127257 A1 May 8, 2014 DERMATOLOGICALLY EFFECTIVE YEAST skin. Against the background of consumers’ uncertainty with EXTRACT respect to genetic engineering techniques, there is a particular demand for corresponding agents that can be regarded, 0001.
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
  • Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones by Ming-Hsiu Yang Su

    Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones by Ming-Hsiu Yang Su

    Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones By Ming-Hsiu Yang Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy Chairperson Ryan A. Altman Michael D. Clift Apurba Dutta Michael F. Rafferty Jon A. Tunge Date Defended: April 26, 2017 The Dissertation Committee for Ming-Hsiu Yang certifies that this is the approved version of the following dissertation: Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones Chairperson Ryan A. Altman Date Approved: April 26, 2017 ii Abstract Ming-Hsiu Yang Department of Medicinal Chemistry, April 2017 The University of Kansas Fluorine plays an important role in drug design, because of some unique features imparted by fluorine. The incorporation of fluorine into small molecules can modulate molecular physicochemical properties, metabolic stability, lipophilicity, and binding affinity to the target proteins. However, few fluorinated molecules are biosynthesized by enzymes. This means incorporating fluorine into the molecules relies on synthetic methods. Thus, efficient synthetic strategies to access the molecules bearing a variety of privileged fluorinated moieties are important for drug discovery. Fluoroalkenes are an isopolar and isosteric mimic of an amide bond with distinct biophysical properties, including decreased H-bond donating and accepting abilities, increased lipophilicity, and metabolic stability. Moreover, fluoroalkenes can also serve as probes for conducting conformational analyses of amides. These potential applications require the development of efficient methods to access fluoroalkenes. In chapter 2, a Shapiro fluorination strategy to access peptidomimetic fluoroalkenes is demonstrated.
  • Breast Cysts and Aluminium-Based Antiperspirant Salts

    Breast Cysts and Aluminium-Based Antiperspirant Salts

    Breast cysts and aluminium-based antiperspirant salts Article Published Version Creative Commons: Attribution 4.0 (CC-BY) Open access Darbre, P. (2019) Breast cysts and aluminium-based antiperspirant salts. Clinical Dermatology: Research and Therapy, 2 (1). 128. Available at http://centaur.reading.ac.uk/88553/ It is advisable to refer to the publisher’s version if you intend to cite from the work. See Guidance on citing . Publisher: Scientific Literature All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement . www.reading.ac.uk/centaur CentAUR Central Archive at the University of Reading Reading’s research outputs online Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids.
  • Review of the Regulation of Products at the Interface Between Cosmetics and Therapeutic Goods

    Review of the Regulation of Products at the Interface Between Cosmetics and Therapeutic Goods

    PO Box 100, Woden ACT 2606, Australia Review of the regulation of products at the interface between cosmetics and therapeutic goods 18 March 2005 Review of the regulation of products at the interface between cosmetics and therapeutic goods March 2005 Prepared for the TGA by David B Newgreen Review of the regulation of products at the interface between cosmetics and therapeutic goods CONTENTS ABBREVIATIONS ..........................................................................................................ii ACKNOWLEDGMENTS .............................................................................................. iii TERMS OF REFERENCE ..............................................................................................iv SUMMARY.....................................................................................................................vi RECOMMENDATIONS..................................................................................................x 1. INTRODUCTION ......................................................................................................13 2. OVERVIEW OF THE REGULATION OF MEDICINES AND COSMETICS IN AUSTRALIA AND NEW ZEALAND ....................................................................23 2.1 AUSTRALIA......................................................................................................23 2.2 NEW ZEALAND ...............................................................................................33 3. OVERVIEW OF THE REGULATION OF MEDICINES AND COSMETICS IN
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep

    (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep

    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
  • Opinion of the Scientific Committee on Consumer Safety on O

    Opinion of the Scientific Committee on Consumer Safety on O

    SCCS/1613/19 Final Opinion Version S Scientific Committee on Consumer Safety SCCS OPINION ON the safety of aluminium in cosmetic products Submission II The SCCS adopted this document at its plenary meeting on 03-04 March 2020 SCCS/1613/19 Final Opinion Opinion on the safety of aluminium in cosmetic products – submission II ___________________________________________________________________________________________ ACKNOWLEDGMENTS Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are: For the preliminary and the final versions SCCS members Dr U. Bernauer Dr L. Bodin (Rapporteur) Prof. Q. Chaudhry (SCCS Chair) Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG) Prof. M. Dusinska Dr J. Ezendam Dr E. Gaffet Prof. C. L. Galli Dr B. Granum Prof. E. Panteri Prof. V. Rogiers (SCCS Vice-Chair) Dr Ch. Rousselle Dr M. Stepnik Prof. T. Vanhaecke Dr S. Wijnhoven SCCS external experts Dr A. Koutsodimou Dr A. Simonnard Prof. W. Uter All Declarations of Working Group members are available on the following webpage: http://ec.europa.eu/health/scientific_committees/experts/declarations/sccs_en.htm This Opinion has been subject to a commenting period of a minimum eight weeks after its initial publication (from 16 December 2019 until 17 February 2020). Comments received during this time period are considered by the SCCS. For this Opinion, some changes occurred, in particular in sections 1, 3.2, 3.3.4.5, 3.3.8.1, 3.5, as well as in related discussion parts and conclusion (question 1). The list of references has also been updated.
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1

    Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1

    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01